Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Michael Phillips is the Director of Business Development
in the Imaging Institute at the Cleveland Clinic. Dr. Phillips is a member of
the Board of Governors of the Cleveland Clinic and is the Co-Chair of the Care
Affordability Task Force which identifies and develops ways to improve the
efficiency and lower the cost of care delivered at the Cleveland Clinic. Dr.
Phillips is interested in the economics of medicine, particularly the business
challenges facing academic medical centers in a changing healthcare
Previously Dr. Phillips served as the Vice Chairman of
Research and Academic Affairs in the Imaging Institute and Section Head for the
Section of Imaging Sciences at the Cleveland Clinic. Dr. Phillips authored or
co-authored numerous articles and book chapters. The underlying goal of his
imaging research was to develop functional metrics to better understand and
more directly measure disease progression in neurodegenerative diseases. His
research was funded by multiple sources including the NIH, State of Ohio, the
National Multiple Sclerosis Society, and the Department of Defense.
Since 2002, Dr. Phillips has been a practicing clinical
neuroradiologist at the Cleveland Clinic. After completing his undergraduate
studies at Amherst College in Massachusetts, Dr. Phillips went on to study
medicine and earn his medical degree from Columbia
University in New York City. Subsequently, he did a
radiology residency at Johns Hopkins Hospital and a neuroradiology fellowship
at the University of Pennsylvania. He received an MBA from the University of
Michigan in 2013.
diffusion/perfusion imaging, Functional Mri, imaging of Parkinson's Disease, imaging of RS
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 10/18/2015, Dr. Phillips has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.